Ertugliflozin significantly improves glycaemic outcomes in patients with type 2 diabetes (T2D) who have stage 3 chronic kidney disease (CKD), according to a subgroup analysis of the VERTIS CV* trial presented at ADA 2021.
In drug-naïve Chinese patients with type 2 diabetes (T2D), treatment with the first-in-class, glucose sensitizer dorzagliatin led to sustained glycaemic control, according to updated findings from the 52-week phase III SEED* study presented at ADA 2021.
Isolation during the COVID-19 pandemic may lead to deterioration in comorbidities and mental health, according to two studies presented at the European Society of Endocrinology virtual conference (e-ECE 2021).
Once-daily iGlarLixi is superior to twice-daily premixed biphasic insulin aspart 30 (BIAsp 30) in glycaemic control and reducing body weight, along with less risk of hypoglycaemia, in patients with suboptimally controlled type 2 diabetes (T2D) despite treatment with basal insulin plus oral antihyperglycaemic drugs (OADs), according to the SoliMix trial presented at ADA 2021.
New drug applications approved by US FDA as of 01-15 July 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
An increasing trend in polypharmacy has been observed in both older and middle-aged people with diabetes, particularly in patients between 55 and 64 years of age, according to a study. However, a decrease in potentially inappropriate medication (PIM) is seen in older patients with polypharmacy.